Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids

Register of interests (PDF 153 KB)

Equality Impact Assessment (Guidance development) (PDF 146 KB)

Appeal

FEmISA : Appeal letter (MSWord 51 KB)

: Scrutiny letter (MSWord 75 KB)

FEmISA : Response to scrutiny letter (MSWord 26 KB)

: Final scrutiny letter (MSWord 69 KB)

Appeal decision (MSWord 48 KB)

Final draft guidance

Final appraisal document (PDF 364 KB)

Committee papers (PDF 7.06 MB)

Public committee slides (PDF 1.12 MB)

Final scope (PDF 173 KB)

Final stakeholder list (PDF 156 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 133 KB)

Equality impact assessment (Scoping) (PDF 122 KB)

Draft scope (PDF 187 KB)

Provisional Stakeholder List (post-referral) (PDF 167 KB)